Gene Based Drugs
The best tips and advice from our vast library of articles, videos, and business tools
Browse Related Topics
Newly Added Articles
- New York lawmaker says ground-zero redeveloper...
- Budget Crisis Creates Financial-Aid Overload at...
- Washington Ranchers Part Ways over Mad Cow Fallout.
- Texas Firm's Suit Poses Threat to British...
- Importing Investments
- Developer Toll Brothers shows off plans for...
- San Antonio Express-News G. Chambers Williams III...
Article Archives
1-20 (of 1320) related articles
Search Results
|
1-20 (of 1320) related articles
Items per page
| |
|
Icoria.
RESEARCH TRIANGLE PARK -- Icoria, which researches gene-based drugs, agreed to sell some agricultural assets to St. Louis-based ... (PERIODICAL ARTICLE)
Human Genome Sciences licenses human gene technology
to Genentech.
Human Genome Sciences, Inc. (Rockville, MD) formed a license agreement with Genentech, Inc. (S. San Francisco, CA) under ... (PERIODICAL ARTICLE)
Introgen licenses fus1 gene from University of
Texas.
Introgen Therapeutics, Inc. (Austin, TX) announced that it has acquired the exclusive worldwide license for the fus1 gene ... (PERIODICAL ARTICLE)
Introgen gains exclusive license to anti-cancer
gene.
Introgen Therapeutics, Inc. (Austin, TX) announced that it has acquired the exclusive worldwide license for the fus1 gene ... (PERIODICAL ARTICLE)
Introgen's mda-7 gene therapeutic receives
patent.
Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) and Columbia University (New York, NY) announced that the United States Patent ... (PERIODICAL ARTICLE)
Introgen Therapeutics' ADVEXIN gene
highlighted.
In an invited session, Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) presented its extensive clinical experience with its lead ... (PERIODICAL ARTICLE)
Introgen's gene therapy establishes basis for
systemic treatment for...
Introgen Therapeutics, Inc. (San Francisco, CA; 512-708-9310) reported data from a Phase I clinical study of the intravenous ... (PERIODICAL ARTICLE)
Introgen's anti-cancer therapy in combination
with established cancer...
The University of Texas (Austin, TX; 512-499-4462) and Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) announced that the United ... (PERIODICAL ARTICLE)
Patent issued for Introgen's cancer
therapeutic.
Introgen Therapeutics, Inc. (Austin, TX) and The University of Texas (Austin, TX) announced that the United States patent ... (PERIODICAL ARTICLE)
The birth of a manufacturing industry
With the selection of two gene researchers, Francis Collins and J. Craig Venter, as Technology Leaders of the ... (PERIODICAL ARTICLE)
diaDexus forms diagnostic license agreements with
Human Genome Sciences.
diaDexus, Inc. (S. San Francisco, CA) announced a license agreement with Human Genome Sciences, Inc. (Rockville, MD) under ... (PERIODICAL ARTICLE)
Key patent obtained for Introgen's Phase 3
product.
Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) and The University of Texas M. D. Anderson Cancer Center (Austin, TX) ... (PERIODICAL ARTICLE)
GenVec signs contract for preventative AIDS
vaccine.
GenVec, Inc. (Gaithersburg, MD; 240-632-5533) announced that it has signed a contract with the Vaccine Research Center at ... (PERIODICAL ARTICLE)
Human Genome Sciences and Medarex announce antibody
collaboration.
Human Genome Sciences, Inc. (Rockville, MD; 301-309-8504) and Medarex, Inc. (Princeton, NJ; 609-430-2880) announced that they have entered ... (PERIODICAL ARTICLE)
Introgen obtains patent for p53 targeted
chemotherapy.
Introgen Therapeutics, Inc. (Austin, TX) and The University of Texas M. D. Anderson Cancer Center announced that the ... (PERIODICAL ARTICLE)
Introgen licenses a family of 10 cancer
genes.
Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) announced that it has licensed a group of newly discovered and sequenced ... (PERIODICAL ARTICLE)
Introgen's viral vector technology awarded
patent.
The University of Texas (Austin, TX; 512-499-4462) and Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) announced that the United ... (PERIODICAL ARTICLE)
UCI researcher seeks 'cure' for the common ulcer
HEADNOTE Medi-Cal Groups Want Piece of the State Budget Pie UCI College of Medicine professor of pathology and ... (PERIODICAL ARTICLE)
Schering-Plough exercises option to develop and
commercialize one of Human...
Human Genome Sciences, Inc. (Rockville, MD; 301-309-8504) announced that Schering-Plough Corporation (Madison, NJ) has exercised one of its ... (PERIODICAL ARTICLE)
Impact of the "new science" of genomics
HEADNOTE FUTURE TRENDS HEADNOTE Breaking a taboo against creating human embryos expressly for medical experiments, scientists at a ... (PERIODICAL ARTICLE) | |
|
1-20 (of 1320) related articles
Items per page
1-20 (of 1320) related articles
|
Newsletter Signup 
- Privacy Policy
We Respect Your Privacy Our Privacy Policy outlines our commitment to your privacy and the importance we place on your trust.
Sponsored Links
Site Map | Contact Us | FAQs | About Us | Media Kit | Reprints | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy
Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.
Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report? | Article Archives
Online Business Database | Online Business Information | Sales and Marketing Solutions | Business Mailing Lists
Online Business Database | Online Business Information | Sales and Marketing Solutions | Business Mailing Lists
Information and opinions on AllBusiness.com solely represent the thoughts and opinions of the authors and are not endorsed by, or reflect the beliefs of,
AllBusiness.com, its parent company D&B, and its affiliates.
AllBusiness.com, its parent company D&B, and its affiliates.
